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1FOREWORD
The Irish Government places a high value on research
as part of its drive to develop a knowledge-based
economy. The Department of Health and Children
contributes to this effort through funding of the
Health Research Board. Since its inception, the HRB
has played a pivotal role in nurturing a culture of
research within the health service. There is no higher
aspiration in science than solving the mysteries of
human disease and there has never been a better
time for focusing research on health. As one of the
wealthiest nations in the world, we have an obligation
to contribute to the global war on disease. Our
scientists are capable, committed and renowned for
their work. The HRB recognises this talent and herein
describes an extraordinary collection of funded
projects across a range of disciplines, from basic
science to research on how well Ireland delivers an
increasingly complex health service. Congratulations
to all of you. You have come through a rigorous
review that places a high premium on innovation and
productivity. Through your efforts, Ireland participates
in humanity’s greatest challenge.
Professor Desmond Fitzgerald
Chairman of the Health Research Board
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The heart of the matter: cardio-vascular disease
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WHAT CAUSES HIGH BLOOD
PRESSURE?
Dr Stuart Bund and PhD student
Jennifer Hughes (Human Anatomy
and Physiology, UCD) believe that
thicker artery walls are a
consequence and not a cause of
high blood pressure
People who have high blood pressure often
have a much thicker muscle layer in the walls
of their small arteries. Until now, it was widely
believed that the thickened muscle caused the
high blood pressure, perhaps by producing a
more powerful contraction. So the received
wisdom was that, to lower the blood pressure,
you should ideally use drugs that also thin the
walls of the arteries. 
In recent years, however, there has been
growing debate about whether this picture is
right. To investigate the relationship between
blood pressure and the thickness of the
artery muscle, we studied sections of blood
vessel in the laboratory using a rig designed to
mimic what happens in the body. The blood
vessels came from rats that have high blood
pressure in one leg, and low blood pressure in
the other. Significantly, we found that the  two
types of blood vessel behaved the same, and
there was no difference between the
contractions of the thick and the thin muscles. 
This leads us to believe that the thicker muscle
wall is actually a consequence of the high
blood pressure, and not a cause of it. Our
results are now being published in international
scientific journals, and if we are right, we may
need to rethink our approach to how we treat
high blood pressure.
THE GENETICS OF HEART
DISEASE
Dr Therese Kinsella and PhD
student Adrian Coyle
(Biochemistry, UCD) are studying
the genetics of blood clotting 
Thromboxane is a natural compound that is
important in regulating blood flow and clotting;
add it to some blood platelets and they will
quickly clump together or clot. This happens
because the surface of each platelet contains
receptors that specifically recognise and
respond to thromboxane. People who have
more of these receptor proteins on their
platelets than normal are at greater risk of
unwanted blood clotting (thrombosis) and of
heart disease. But what determines the
number of receptors on blood cells? 
Humans actually have two types of
thromboxane receptor (all other red-blooded
creatures have just one), called TP-alpha and
TP-beta. Intriguingly, though they have
different compositions, both proteins are
encoded by the same gene. One might expect,
therefore, that their production would be
regulated by the same DNA controlling
sequence (‘promoter’ sequence). Previously,
scientists had discovered one promoter
sequence that was thought to control the
production of both TP-alpha and TP-beta. In
this research, we discovered that the
previously identified promoter sequence
specifically controls TP-alpha expression and
have discovered a new promoter that controls
TP-beta production, independently of TP-
alpha. Our next step is to investigate the
factors that interact with these two promoters,
and ultimately determine how TP-alpha and
TP-beta expression is independently regulated.
This work should identify the individual roles of
TP-alpha and TP-beta and should greatly
improve our understanding of the genetics of
heart disease.
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BLOOD CLOTS AND MOLECULAR
VELCRO
Dr Niamh Moran and Dr Sarah
O'Neill (Pharmacology, Royal
College of Surgeons in Ireland) are
studying how blood clots form
Blood clots can cause strokes and heart
attacks. We still don’t fully know how the clots
form, although we do know that small blood
cells called platelets play an important role,
and people whose platelets are dysfunctional
can suffer serious clotting and bleeding
disorders. If we knew more about what
happens, we might be able to design better
clot-busting drugs. 
One molecule that seems to be important is
called GpIIb/IIIa, which covers about 12% of a
platelet’s surface. This acts as a kind of
molecular Velcro, sticking cells together, but
more than that, it also seems to make a clot
form. We have now discovered that GpIIb/IIIa
is a shape-shifter: when it is activated it
changes structure, making and breaking
several sulphur-sulphur bonds, so that it re-
folds in a different shape. We don’t yet know,
however, what provokes this change.
Significantly, we have also discovered that the
molecule controls this process itself. In other
words, as well as acting as a structural protein,
it can also function as an enzyme.
This sheds considerable light on how GpIIb/IIIa
functions, and there is now growing interest in
our findings. Our next step is to look for
chemicals that block the shape-shifting, as
these could be useful as drugs to prevent 
clots forming.
HOW MOUTH INFECTIONS CAN
DAMAGE YOUR HEART
How do bugs from your mouth
cause blood clots and heart
failure? Dr Dermot Cox and PhD
student Ciara McManus (Clinical
Pharmacology, Royal College of
Surgeons Ireland), think they know
why, and are developing a drug to
prevent it 
Healthy teeth and gums can also mean a
healthy heart! That’s because, in a healthy
mouth, there is less chance of bacteria getting
into the bloodstream (as can happen, for
instance, if your gums bleed when you brush
your teeth). The bacteria to watch for include
Porphyromonas gingivalis, which new research
suggests can cause hardening of the arteries;
and Streptococcus sanguis, the organism we
study, which can trigger blood clots in already
damaged heart valves. 
To understand how these clots form, we studied
the way the bacteria interact with the platelet
cells (the blood cells involved in forming clots).
We discovered that disease-causing strains of
S. sanguis are very good at sticking to platelets,
a process we call adhesion. We also found that
they probably do this by producing a collagen-
like protein that binds to a collagen receptor on
the platelets. This is surprising, because blood
clots usually involve a different protein, called
fibrinogen. Our work has allowed us to identify
a molecule that blocks the adhesion, and
prevents the bacteria and the platelets sticking.
We believe this could lead to a new drug for
preventing this form of ‘infective endocarditis’,
and we are now patenting our discovery, prior
to publishing the results in international journals.
A drug that inhibits this interaction would also
be useful in coronary artery disease, since the
same platelet-collagen interaction is important
in the clot that blocks an artery leading to a
heart attack. 
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Cardiovascular disease
Death rates in Ireland from heart attack have
decreased since the 1980's
but remain high at 176 per 100,000
population compared to the average for
the EU at 108.
In 2001, 11,914 people died from diseases
of the circulation, i.e. 41% of all deaths were
due to cardiovascular disease, stroke and
other diseases of the circulation.
In people under 65, Ireland has the highest
death rate from coronary heart disease in
the EU.
Sources: Central Statistics Office, 2001 and
WHO HEA Database 2002
Diabetes: understanding the causes
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WHY DO MANY DIABETICS
DEVELOP KIDNEY DISEASE? 
Prof Hugh Brady and colleagues
(Mater Hospital, Dublin) are
studying the genes involved in
diabetes and kidney disease
Up to 40% of people who have diabetes also
develop diabetic kidney disease, suggesting
that some diabetics are particularly vulnerable
to this devastating condition. If doctors could
identify susceptible people in advance, they
could intervene with more aggressive early
treatments. So, to search for the genetic
changes that make some people more
susceptible to kidney disease, we collected
DNA samples donated by diabetes patients,
both those with and those without kidney
disease. We also studied kidney cells in the
laboratory, and have identified over 200 genes
which are either switched on or off when the
cells are exposed to high concentrations of
glucose, as happens in diabetes.
From our genetic analyses we have discovered
several genes, including one called caldesmon,
that seems to be important. Caldesmon codes
for something called an actin-binding protein.
Actin binding proteins are vital to maintaining
the structure of the cell and are critical in
supporting the role of the kidney in filtering
blood. One particular form of the caldesmon
gene is frequently seen in diabetics with kidney
disease. Our next step is to study this gene
further, and also some of the other genetic
changes we have identified. The work will shed
light on how kidney cells function, and may
ultimately allow us to develop diagnostic tests
to identify diabetics at risk, and perhaps even
treatments for kidney disease.
DIET AND DIABETES 
People with Type II diabetes
should eat less animal fat and
more polyunsaturated oils, based
on findings from Dr Philip
Newsholme and a multidisciplinary
team, including postdoctoral
scientist Lorraine Brennan, MSc
student Áine Shine and PhD
student Gordon Dixon (Conway
Institute and Biochemistry, UCD) 
People who suffer from Type II diabetes not
only have high glucose levels in their blood,
they also have more saturated fatty acids in
their bloodstream. This leaves them open to
coronary heart disease, a major complication of
Type II, or late-onset diabetes. We have
discovered, however, that the saturated fatty
acids can make the diabetes worse, by
affecting the all-important insulin-producing
beta cells in the pancreas. The fatty acids
reduce the cells’ ability to handle nutrients, and
especially the amino acid, alanine, which we
have discovered is crucial in stimulating the
beta cells to secrete insulin. Net result?  The
cells fail to secrete enough insulin, setting up a
vicious circle: the diabetes gets worse, the fatty
acid and glucose levels climb higher, and it’s
harder for the patient to control their diabetes.
Significantly, we have now also discovered
how to break this vicious circle. Studying
insulin-producing cells in the laboratory, we
found that, increasing the concentration of
polyunsaturated oils added to the cells, helps
the cells regain much of their ability to respond
to glucose and amino acids. In the patient, this
would result in more insulin being secreted,
thus enabling greater control over blood
glucose concentrations. These important
results are being published internationally, and
meanwhile, we suggest that people with Type
II diabetes switch to a diet rich in sunflower or
safflower oils, which are primary sources of the
‘right type’ of polyunsaturated fats.
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DYING FOR SOME INSULIN?
Dr Philip Newsholme (Conway
Institute, UCD), Dr John Nolan (St
James's Hospital) and PhD student
Gordon Dixon (Biochemistry, UCD)
are probing the causes of
autoimmune diabetes
Friend or foe? That’s what your immune
system has to find out, so it can identify and
destroy foreign invaders. Sometimes the
system slips up, however, perceiving some of
your own proteins as foreign, and triggering an
autoimmune disease. One such disease is
Type I diabetes, which develops early in life
when, for reasons not yet understood, the
immune system kills off the insulin-producing
beta cells in the pancreas. People with Type I
diabetes must inject themselves with insulin.
Intriguingly, another form of autoimmune
diabetes can develop late in life. In this ‘latent
autoimmune diabetes of adults’ (LADA), the
insulin-producing cells are not killed, however,
but disabled. 
To find what causes these two autoimmune
forms of diabetes, we study pancreatic beta
cells in the laboratory. We have discovered that
one particular component of the immune
system, called complement, dramatically
reduces the ability of beta cells in Type I and
LADA patients to produce insulin. Complement
is activated to high levels when cells in the
laboratory are exposed to blood from Type-1
and LADA patients. Significantly, we also
found that complement reduces the cells’
ability to consume an amino acid called
alanine (derived from protein metabolism); we
believe alanine and glucose are the key
nutrients that trigger beta cells to secrete
insulin. This important finding has just been
published. Our research suggests that Type I
and LADA diabetes have much in common,
but more research is needed to explain what
triggers the complement to attack the cells in
the first place.
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Diabetes
Diabetes affects people of all ages and is now considered a growing epidemic by the
World Health Organisation (WHO). It is estimated that the number of people with
diabetes will double over the next 10 years to 240 million worldwide. At present in
Ireland it is estimated that 200,000 people have diabetes and that 50% of those are
unaware they have the condition.
Diabetes occurs when the sugar (glucose) level in the blood is too high. This happens
when the body is not burning up carbohydrates properly due to a fault in the
pancreas, the gland that produces insulin. Diabetes may be present either when no
insulin is made or when insulin is made but not working properly.
There are two types of diabetes. Type 1, or insulin dependent diabetes, usually
occurs before the age of 35. A person with type 1 diabetes makes no insulin and
therefore needs to inject insulin to control blood sugar levels and remain healthy.
Type 2, or non-insulin dependent diabetes usually occurs after the age of 40 and is
very common in old age. In this case, the person with diabetes makes some insulin,
but it does not work properly.
Source: Diabetes Federation of Ireland
Cancer: causes, treatment and possible cures
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USING VIRUSES TO KILL 
CANCER CELLS
Prof Gregory Atkins (Microbiology,
TCD), and PhD student Ann Marie
Murphy hope to put viruses to 
good use
Virus infections are normally bad news. That's
because when the virus particles get inside
your cells they can breed in great numbers
there, then burst out of the cells that
unwittingly sheltered them, and in the process
kill the cells. But we wondered, could we put
this cell-killing behaviour to good use, and
design a virus to kill cancer cells?
To test our idea, we took cells from human
lung cancers and rat prostate cancers, and
transplanted these into laboratory mice. The
virus we chose for our experiment is a
laboratory strain, called the Semliki Forest
virus vector. However, we gave it some extra
genes that it could use to persuade cells to
commit suicide, a process known as
apoptosis. Then, we infected the cancer cells
with our modified virus, and waited to see
what would happen.
As we hoped, the virus particles persuaded
many of the cancer cells to commit suicide. But
the outcome depended on the type of cancer:
most of the lung cancer cells died, for instance,
while the rat prostate cancer cells do not seem
to have been killed outright, although they were
stopped in their tracks. To explore this
difference, we have begun a new experiment,
looking at further cancer types. Clearly, we are
a long way from clinical trials, but one day we
may use viruses to treat cancer. 
BEATING DRUG-RESISTANT
CANCERS
Prof Martin Clynes, Dr Robert
O’Connor (National Institute for
Cellular Biotechnology, DCU) and
Dr Anita Maguire (Chemistry, UCC)
are looking for new drugs that
would make chemotherapy more
effective
Chemotherapy is now widely used to treat
cancer, but unfortunately some cancer cells
are resistant to the drugs used. This could
happen if the cancer cells possess a ‘drug
pump’: in essence, an enzyme that pumps the
chemotherapy drug out of the cell, and allows
the cancer to survive. Needless to say, the
hunt is on to find chemicals that can inhibit 
drug pumps.
Intriguingly, some non-steroidal anti-
inflammatory drugs (NSAIDs), including those
widely used to treat diseases such as arthritis,
seem promising. Our group has already shown
that one of these, indomethacin, can inhibit a
particular drug pump known as ‘multi-drug
resistant protein 1' (MRP-1). Also we have
shown in the laboratory that, when you
combine this drug with the standard
chemotherapy drugs, you can successfully kill
more cancer cells. A small clinical trial is now
underway, to see if this effect can improve
specific cancer therapies for patients.
Meanwhile, we want to see if we can design a
new drug that is even better at inhibiting the
drug pump, and hopefully is also less toxic.
For this, we manufactured over 30 different
derivatives of indomethacin (UCC), and then
screened their performance in the laboratory
(DCU). From these we have identified two new
compounds that are very effective at inhibiting
the MRP-1 drug pump. We are hopeful that,
one day, this approach will help to improve the
success rate of chemotherapy.
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NEW SCREENING TEST FOR
CERVICAL CANCER
Prof John O’Leary and his team,
including PhD student Niamh
Murphy (Pathology, Coombe
Women's Hospital, Dublin) have
invented a radical new test for
cervical cancer that is fast and
effective and already attracting
considerable international interest
Cervical cancer is a major health problem for
women, but one which can be difficult to test
for. That’s because, in the conventional test,
thousands of cervical cells are smeared on a
glass microscope slide, then someone must
laboriously examine the cells down a
microscope, looking for abnormalities. It is time-
consuming and tedious work, and depends on
an individual’s subjective judgment. Although
some laboratories ask two or sometimes three
people to examine every slide, an abnormality
can occasionally be missed.
So the search was on for a new test, fast and
effective, easy-to-use, and not dependent on
an examiner’s personal judgment. We believe
we have invented just such a test.
Instead of looking down a microscope for
abnormalities, our test is essentially a
chemical reaction that detects the genetic
changes which occur in an abnormal cell.
We considered five genetic changes, or
markers, one of which, called p16, we found in
all abnormal cervical cells. This forms the basis
for our screening test: simply add p16
antibody to the cervical cells, and if any are
abnormal, the mixture changes colour. The test
takes just a couple of hours, and is so simple it
can be done by a machine.
The other four genetic markers (called HPV,
MCM5, CDC 6, and telomerase) yield additional
information on the seriousness of the
abnormality, and provide a valuable second test
when the first one shows a problem: by
combining information from all five markers, we
can categorise women who are at risk of
developing cervical cancer into low, medium and
high risk groups, depending on which markers
they have. This gives us a kind of ‘molecular
traffic light’ screening approach, with green (low
risk), orange, and red (high risk) channels.
Already there is considerable international
interest in our test and, to make it as widely
available as possible, we have decided not to
patent our invention. Trials are under way in
several countries to refine the procedure, and
we are now talking to companies about
designing a machine to automate the test. It is
a fine success story for Irish research, and one
which should make a major contribution to
improving women’s health and the detection
rate of cervical cancer.
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UNDERSTANDING HOW BREAST
CANCER CELLS SURVIVE
Prof Finian Martin and PhD student
Janice Murtagh (Pharmacology,
UCD) are studying the chemical
signals that are essential for 
cell survival
If we are ever to fully understand how tissues
become diseased, we must first know how
normal, healthy tissues grow and behave and
organise their cells. We can then use this
fundamental information to understand
diseases and to learn how to treat them. So in
our research into breast cancer, we study the
behaviour of breast cells that are normal but
have the ability to change (transform) and grow
into tumours.
We study these breast cells in the laboratory,
by maintaining them in suitable bathing fluids
and supporting them on a specialised natural
protein scaffold called an extra-cellular matrix.
This allows us to study the cells’ 2-dimensional
and 3-dimensional organisation. From this, we
were able to identify the key molecules that are
used to carry the signals, inside the cells, that
are essential for cell survival. While the various
signals had previously been known, we were
the first to show that cells need these signals if
they are to organise properly.
Our work also explains why many tumour cells
resist efforts to switch off the survival signals
(indeed, many tumour cells actively produce
molecules that keep these survival signals going).
Providing an in-depth description of this ‘survival’
signalling pathway, as we have, suggests ways
we could make it more difficult for cancer cells to
survive, and may help the design of new drugs
for combating breast cancer.
CASTRATION AND CANCER 
Mr Kevin McEleny, Dr William
Watson and Prof John Fitzpatrick
(Mater Misericordiae University
Hospital, and Conway Institute,
UCD) are studying the life and
death of prostate cancer cells
The male hormone androgen is vital to the
survival of prostate cancer cells: deprive them
of androgen, and most of them die.
Consequently, the main prostate cancer
treatment is ‘androgen-deprivation therapy’ - in
a word, castration. Whether by drugs or
surgery, this removes the androgen, and forces
the tumour cells to kill themselves through a
process called apoptosis. Some tumour cells
eventually become resistant, as they devise a
way of surviving without the androgen, and the
tumour recurs. To find out how, we are
studying apoptosis in prostate cancer cells in
the laboratory, and in tumour cells taken from
prostate cancer patients.
The enzymes that trigger apoptosis are called
caspases; and they can be prevented from
acting by certain ‘inhibitor of apoptosis
proteins’ (IAPs). When you deprive prostate
cancer cells of androgen, it seems they switch
off their IAP genes, the caspases can then act,
and the cells essentially commit suicide. To
understand what happens in tumour cells that
are resistant, we looked at which proteins are
present and which are absent. We found that
the resistant cancer cells have more of the
IAPs that are seen in aggressive tumours. We
believe these IAPs keep the cells alive by
inhibiting the caspases, and preventing
apoptosis. As proof of this, when we switched
off the IAP genes in prostate cancer cells in
the laboratory, we found that more of them
died. This might one day lead to a new
treatment for prostate cancer.
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THE GENETICS OF
INFLAMMATORY BOWEL
DISEASE
Dr John Morgan (Microbiology,
UCC), Prof Fergus Shanahan (Cork
University Hospital) and
colleagues, and PhD student Avril
O’Riordan are investigating the
genetic changes associated with
bowel disease and colon cancer
People who have had a longstanding
inflammatory bowel disease (IBD) are more at
risk of developing colon cancer than healthy
people. To understand why this should be, we
are investigating the genetic changes that
occur in the colon of people who have had IBD
for at least 20 years. 
For this study we were able to call on a potent
new technique, known as gene chip, or gene
array, technology, that essentially provides a
snapshot of the genes that are active in cells
at any time. Turning this technique on biopsy
material taken from IBD patients revealed that
genes associated with inflammation are
switched on in their colon cells. This confirms
what one would expect for an inflammatory
disease. We also applied this technique to
biopsies taken from mice, who are genetically
predisposed to developing IBD-like disease,
and found that, as their disease progressed,
their colon became increasingly inflamed, and
significantly, the activity of the inflammation
genes also increased. While more work is
needed to identify the genes that make some
people susceptible to colon cancer, ultimately,
this genetic approach might help us develop a
diagnostic test for IBD and colon cancer.
WHAT MAKES SOME CANCER
CELLS MALIGNANT?
Dr Aideen Long, Prof David Croke
and PhD student Eilis Foran
(Biochemistry, Royal College of
Surgeons in Ireland) are studying
the genetic changes that make
some tumour cells malignant
Why do some cancer cells become malignant,
leaving the primary tumour site, and forming
secondary tumours elsewhere in the body? To
answer this, we are studying the genetic
differences between primary tumour cells, and
malignant or metastatic secondary tumour
cells. Our first cell line (SW480), was taken
from a primary colon tumour, the other
(SW620) comes from a secondary tumour in
the lymph node. Both have been widely
studied around the world, and significantly,
both came from the same person, and so have
the same genetic make-up.
We previously compiled ‘gene expression
profiles’ for these two cell lines, showing which
genes are switched on at any time. This
revealed nearly 100 differences between the
primary and the malignant cells (ie, genes
switched on in one cell, and switched off in the
other). Now, we want to identify the changes
that make the SW620 cells malignant, and for
this project focused on one gene, L-Plastin,
which is associated with malignant cancers: in 
general, the more active the L-Plastin gene,
the more aggressive the tumour. 
So we modified the primary tumour cells
(SW480), switching on their L-Plastin gene,
and found that these cells now grew faster.
Significantly, we also discovered that this
modification switched off a gene called E-
cadherin, which is responsible for sticking cells
together in tissues. The loss of expression of
this gene may play a role in the metastatic
spread of tumours.
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THE SEARCH FOR BETTER
CANCER TREATMENTS
Dr Paul Ryan (Cork Cancer
Research Centre, UCC) has found
a way to detect the tiny tumours
that sometimes escape a patient’s
initial cancer treatment
Many cancer patients will undergo not just
one, but often two and sometimes even three
different therapies. They might have
chemotherapy, for instance, combined with
radiotherapy, and then surgery, the aim being
to kill as many cancer cells as possible. But
despite our best efforts, some tumour cells
may escape even this multi-pronged attack. 
If they spread to form secondary tumours
elsewhere, then the outlook is poor. We have
used a new technique to help in the study of
how cancer spreads.
We study oesophageal cancer, a disease
where, sadly, the outlook is often poor: in up to
80% of patients undergoing surgery, tiny
clumps of tumour cells have already broken
away and spread elsewhere. Called micro-
metastases, these tumour cells are too small
to be detected by conventional means such as
CT scans. However we have detected them in
rib bone marrow in a majority of oesophageal
cancer patients, and our results have been
replicated by scientists in Italy. Our study
sheds light on the nature of tumour cell
spread: if micrometastases are present in rib
bone marrow, they are probably present
elsewhere. Our technique is therefore a useful
new tool for evaluating how successful cancer
therapies are at clearing tumours.
THE CAUSES OF MALIGNANT
LYMPHOMA 
As part of a European study, 
Dr Anthony Staines and colleagues
(Public Health, UCD) are
investigating the causes of
lymphomas and leukaemias 
in Ireland
It is now generally accepted that some
cancers, notably leukaemias and lymphomas,
can be caused by exposure to certain viruses
and cancer-causing chemicals. A major EU
study (called Epilymph) is now underway
across Europe to investigate this, and we are
conducting the Irish analysis. For this, we
recruited 200 people here who have either a
leukaemia or a lymphoma, and 200 healthy
people for a comparison. All the data were in
by March 2003, and we are now analysing the
information, and expect to have the final
results by the end of 2004. 
So far, none of the countries taking part in the
study has reported any findings regarding
occupational exposure to chemicals at work.
The Spanish team have reported, however,
that the hepatitis-C virus is an important cause
of lymphomas in Spain. However as hepatitis-
C is relatively uncommon in Ireland, we do not
expect that it will be a major cause of
lymphoma here. 
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KILLER CELLS IN THE LIVER
Dr Derek Doherty and PhD student
Tony Kenna in collaboration with
Drs Cliona O’Farrelly and John
Hegarty (St Vincent's University
Hospital, and Institute of
Immunology, NUI Maynooth) are
studying some natural immune
system lymphocytes that can kill
cancer cells
The immune system produces many types of
cells in its fight against infection and disease.
Many are involved in recognising and killing
‘foreign bodies’, but natural killer 
T-lymphocytes can recognise ‘friendly’ cells
that have become cancerous. Activate these
NKT cells in mice, and they can seek and
destroy liver cancer cells, for instance. But,
does the same thing happen in people?
We compared NKT cells in mice and people,
and significantly, found major differences.  For
instance, up to 40% of T cells in a mouse liver
will be NKT cells, and the figure for blood is
5%.  But in humans, we find fewer NKT cells:
0.5% of liver T cells, and 0.01% in blood.
Furthermore, mouse and human NKT cells
function differently: in mice, just one type of
molecule helps NKT cells to tell friend from foe
(called the ‘antigen-presenting molecule’, or
CD1); but humans have at least five, and
possibly more. 
So do NKT cells play a role in killing cancer
cells in humans? If this was so, you would
expect cancer patients to have higher NKT
levels.  However, when we analysed samples
from a number of colon cancer patients we
discovered they had fewer NKT cells, although
they had more of another type of immune
system lymphocyte, called gamma delta T
cells. Clearly, there is much we have yet to
learn.  NKT cells are powerful and important,
and we may one day treat cancer by controlling
them, but we have shown that what works in
mice will not necessarily apply in humans.
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Cancer
More than 21,000 Irish people will develop
cancer this year, and 7,800 will die of the
disease. Cancer numbers are increasing by
about 1.5% every year, mainly due to
population growth and aging
Cancer causes one-quarter of all deaths in the
State and is the largest single cause of death
Cancer is responsible for more than half of the
deaths of women aged between 40 and 60
The commonest type of cancer is skin (non-
melanoma) followed by breast, colorectal,
lung, and prostate.
Source: The National Cancer Registry
Tummy trouble: food poisoning, gastritis and heartburn
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MEET THE GERM THAT CAN
CAUSE STOMACH CANCER
Two TCD research teams are
studying Helicobacter pylori, the
bacterium that can cause stomach
cancer and gastritis
First, Prof Cyril Smyth and PhD
student Ian Carroll (Microbiology,
TCD) are curious as to why some
strains of the bacterium are more
dangerous than others
Helicobacter pylori is a major health hazard. It
can cause stomach and duodenal ulcers,
gastritis, and even some forms of stomach
cancer. Stomach cancer is a major killer,
second only to lung cancer in the league of
cancer deaths, so it is no surprise that the
WHO rates H. pylori as a Class I carcinogen.
Amazingly, over half the world’s population is
infected with this bacterium (most people
catch it when they are young, usually from a
family member who is infected). Even more
intriguing, is that many people will never
develop any symptoms, and may never know
that they are infected. We wondered if this is
because some strains of the bacterium are
more likely to cause disease than others.
To investigate this, we studied bacteria from
individuals and from members of Irish families
infected with H. pylori. Comparing the genetic
fingerprints revealed that family strains of
bacteria were very similar. The Irish isolates
were closely related to other northern
European and eastern Asian strains. Next, we
focused on a particular gene called cagA,
which is thought to be involved in triggering
the gastric problems.  Our initial results
suggest that the length of the bacterium's
cagA gene, may be associated with the ability
of the bacterium to cause disease or to lie
silent and dormant. We intend to investigate
this tantalising finding further.  
Prof Colm Ó Moráin, Dr Barbara
Ryan, and PhD student Gwen
Murphy (Clinical Medicine, TCD,
Adelaide & Meath Hospital), are
studying why some people are
more susceptible to infection
Why do some people, when infected with H.
pylori, develop stomach cancer while others
remain asymptomatic? It could be that their
immune system is highly sensitive, and over-
reacts to the infection, triggering excessive
inflammation which may do more harm 
than good. 
Inflammation is important: gastritis, and a
related disorder called intestinal metaplasia
(thought to be an early stage in the
development of stomach cancer) are both
forms of inflammation, provoked by a patient’s
immune system in response to the H. pylori
infection. One gene involved in provoking
inflammation, IL-1B, is associated with an
increased risk of developing some forms of
stomach cancer.
We investigated whether this and another
inflammation gene, TNF, were associated with
gastritis and intestinal metaplasia in patients
infected with H. pylori. We studied these genes
in 100 patients with H. pylori -related gastritis,
and 60 patients with H. pylori -related intestinal
metaplasia, and compared these with the
results for 100 asymptomatic H. pylori -negative
controls. In contrast to previous studies, we
found no association between a person’s TNF
and IL-1B genes and their susceptibility to a H.
pylori gastric disease. This may mean there are
several routes to stomach cancer, and that
some do not involve the  protein from the IL-1B
gene. Clearly, more research is needed. Projects
such as ours are beneficial not only in studying
H. pylori -related disease but also in
understanding inflammation and its implications
for the development of cancer.
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HOW YOUR DIAPHRAGM KEEPS
A GRIP ON YOUR OESOPHAGUS
Dr James Jones (Human
Physiology, UCD) and Dr Deirdre
Campion (Veterinary Physiology,
UCD) with PhD student Mark
Pickering, are investigating the
relationship between breathing 
and eating 
Heartburn, difficulty swallowing, and an
ulcerated oesophagus . . . Just some of the
symptoms associated with gastro-
oesophageal reflux disease. That’s the
technical term for what happens when the ring
of muscle at the base of your oesophagus
relaxes, allowing your stomach contents to
reflux with every breath. Some people are
particularly susceptible to reflux, and we’d like
to know why.
The muscle in question is your breathing
muscle, the diaphragm, which forms a cross-
shape, called the crural diaphragm, at the base
of the oesophagus. To understand what
happens in gastro-oesophageal reflux disease
when the crural diaphragm temporarily fails,
we studied the nerves controlling various parts
of the diaphragm. We discovered that, first,
nerves supplying the crural diaphragm are
subtly different from the nerves supplying the
rest of the diaphragm; and second, that there
are not one but two nerve pathways carrying
pain information from the oesophagus to the
brain. This new anatomical information 
could be important for doctors treating
oesophageal pain.
But why should a breathing muscle be so
important in digestion? Perhaps the diaphragm
originally evolved to control the oesophagus?
To answer this evolutionary question we
looked at the pipid frog Xenopus laevis. It has
a muscle which, like our diaphragm, encircles
the oesophagus, and was thought to move air
in and out of the frog’s lungs. We found that
this muscle attaches to the oesophagus near
the stomach, and when it contracts,
oesophageal pressure increases. So we now
believe the diaphragm probably evolved as an
aid to digestion, rather than breathing.
A NEW FOOD POISONING
BACTERIUM
Dr Adele Mooney and Dr Billy
Bourke (Children's Research
Centre, Our Lady's Hospital for
Sick Children) have greatly added
to our knowledge about
Campylobacter upsaliensis
One of the major causes of food poisoning are
the Campylobacter family of bacteria.  The
most common and best-known member is 
C. jejuni, but a relatively new species called 
C. upsaliensis, which was discovered only in
1982, is now recognised as an important
cause of diarrhoea, especially in children.  Not
much is known about it, not least because it is
difficult to work with and to grow in the
laboratory.  However, we have managed to
conduct a number of experiments which help
explain how C. upsaliensis causes disease.
First, we have shown that C. upsaliensis
possesses the gene for a toxin called cyto-
lethal distending toxin. Several other food
poisoning organisms, such as E. coli, also
produce this toxin, which prevents cells
completing their normal cell cycle. This toxin
probably explains our second finding, which 
is that if you add some C. upsaliensis to
cultures of human intestine and immune cells
growing in the laboratory, the cells are
prevented from reproducing and ultimately die
through a form of cell suicide called apoptosis.
Finally, we have also shown that
C. upsaliensis bacteria are good at invading
both tissue culture cells grown in the
laboratory and cells taken directly from the
lining of the small bowel.  Taken together,
these findings are a valuable insight into how
C. upsaliensis causes disease, and should help
in the search for a treatment.
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In the mind: memory and brain disorders
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THE SCIENCE OF
ABSENTMINDEDNESS
Why are older people more absent-
minded? Prof Ian Robertson and
PhD student Nicola Porter
(Psychology, TCD) are investigating
with their ‘oops test’
Oops! It is easy to make a simple mistake
when we are doing something routine,
because we are not paying attention to what
we are doing. Why are some people more
prone to this absent-mindedness than others?
To study this in the laboratory, we ask people
to take our Oops Test. It is a relatively simple
task: just press a button every time a number
shows on the screen, but not if the number is
3. The trick is that the 3 doesn't appear very
often and people can be easily 'lulled' into
pressing it by mistake. 
We find that older people make more mistakes
on this test than their younger counterparts. By
recording people’s brain activity while they are
doing our test, we can see that the pattern of
activity is different in a young person compared
to an older person. This is also true of young
people who are very good at maintaining their
attention (and consequently make fewer absent-
minded slips) compared to those with poor
concentration. Ultimately, we want to improve
people’s attention and memory skills, and we are
now designing exercises that will hopefully help
older people to become less absent-minded.
MEMORIES ARE MADE OF THIS
Dr Áine Kelly and Prof Marina
Lynch (Physiology, TCD) are
studying what happens in the brain
when we learn and remember
something
Thinking involves nerve cells in the brain
signalling to, or communicating with, each
other. Learning and remembering are thought
to occur when connections between nerve
cells are strengthened, but this process
declines with age and is impaired in patients
with neurodegenerative diseases such as
Alzheimer's disease. Neurobiologists are
attempting to identify the causes of the decline
by studying an animal model of learning 
and memory called call long-term 
potentiation (LTP). 
For our investigation into LTP (and, by
extension, learning and memory), we focused
on a natural brain chemical called nerve
growth factor (NGF), which improves the
growth and survival of nerve cells. By studying
the brains of rats, we were able to examine the
cellular changes that happen during LTP and
to follow the signalling pathways that are
stimulated by NGF. Significantly, we identified
one pathway that is more active when LTP
occurs. We also identified one protein in this
pathway, ERK, that is required for
consolidating memories. This sheds light on
how memories are made, and ultimately it may
help scientists to design new treatments to
prevent, or possibly even cure, neuro-
degenerative diseases.
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FISH OIL IS GOOD FOR 
YOUR BRAIN
Prof Marina Lynch, PhD student
Emily Vereker and MSc student
Peter Lonergan (Physiology, TCD)
believe that eating fish oil could
help protect your brain from
neurodegenerative diseases
Older people, and people with
neurodegenerative disorders such as
Alzheimer’s disease, have trouble remembering
and learning. These problems seem to arise
because the hippocampus region of the brain,
which plays an important role in memory and
learning, is particularly susceptible to damage.
That damage might be simply accumulated
‘wear and tear’, or perhaps caused by some
disease. Either way, the immune system often
responds to such damage by triggering
inflammation. Our laboratory has previously
shown that this inflammation causes brain
cells to become stressed and eventually die,
just as in an older brain. We have also
discovered that exposing rats to radiation
triggers the same inflammation, and the same
kind of brain cell damage. The net result is a
reduction in the nerve cell signalling that is
associated with learning.
We have now discovered, by studying the
brains of rats, that one protein involved in
provoking the inflammation reduces the
polyunsaturated fatty acids in the membrane
of the nerve cells, making the cell membranes
more rigid. Significantly, when we fed rats a
diet that included a polyunsaturated fatty acid
found in fish oil (eicosapentaenoic acid, or
EPA), it helped protect their brain from this
kind of damage, and even reversed the
damage caused by radiation. Our evidence
suggests that the EPA works by increasing the
amount of an anti-inflammatory protein in the
brain. These discoveries could have significant
implications for the treatment of people with
neurodegenerative diseases.
UNDERSTANDING PARKINSON’S
DISEASE
Dr Kieran McDermott, Dr Aideen
Sullivan and PhD student Terri
Wood (Biosciences, UCC) are
studying the neurobiology of nerve
cells in the brain
If you could peer inside the brain of somebody
who has Parkinson’s disease, then you would
see that certain nerve cells in the substantia
nigra were progressively degenerating and
dying. These are the dopamine-producing
neurons, and their loss causes profound
effects. Normally, our brain produces
chemicals called neurotrophins, which
encourage nerve cells to grow and survive,
and several researchers are experimenting with
these to treat Parkinson’s. But while some 
positive effects are seen, overall the results 
are ambiguous.  
As neurobiologists, we are keen to understand
how neurotrophins affect nerve cells, how the
various nerve cells interact, and why
dopamine-producing neurons sometimes
die. So we took cells from the substantia nigra
(both dopamine-producing neurons and the
glial cells which provide them with essential
support), grew them in the laboratory, and
looked at the effect of adding two
neurotrophins, GDF-5 and GDNF. Adding both
together doubled the survival rate of the
neurons, but it also increased the number of
glial cells. Our next step is to understand why:
do more neurons survive simply because there
are now more glial cells? Or do the
neurotrophins have a direct effect on the
neurons? This information could help in
treating Parkinson’s disease: one experimental
operation involves transplanting stem cells 
into a patient’s brain, but the transplanted 
cells don’t survive well. Our results suggest
that adding the GDF-5 and GDNF
neurotrophins might improve the success 
rate of these transplants.
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THE BRAIN, THE IMMUNE
SYSTEM AND ALZHEIMER’S
DISEASE
Dr John O'Connor and PhD
student Hilary Murray (Physiology,
UCD) are studying how the
immune system can hit our ability
to learn and remember
Ever noticed how, when you are ill with an
infection, it can be harder to learn and
remember things? That’s because some of the
compounds your immune system produces to
fight the infection have a downside: they can
also affect the brain processes involved in
learning and remembering. This also explains
some of the symptoms seen in
neurodegenerative diseases such as
Alzheimer’s and Parkinson’s: in these cases,
the immune system triggers inflammation in
the brain, perhaps because it wrongly
perceives the brain damage as some kind of
infection that needs to be fought.
The immune chemicals involved include a
group of proteins called cytokines, which are
important in triggering inflammation. To
understand how these affect learning
processes, we studied rat brain, which we keep
bathed in artificial cerebral-spinal fluid in the
laboratory. When we add a cytokine to the
fluid, it reduces the nerve cell communications
(called ‘long-term potentiation’) that are
fundamental to learning. We have now
discovered two proteins (called JNK and p38)
which inhibit the cytokine, and restore the long-
term potentiation. As well as shedding light on
how brain inflammation can cause neurological
problems, our discovery suggests new avenues
to explore in the search for drug treatments for
Alzheimer’s and Parkinson’s disease.
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Alzheimer’s disease
It is estimated that 33,000 people in the Republic of Ireland have dementia. Most of
these have Alzheimer's disease, which is the most common cause of dementia and
represents about 60% of all cases. Alzheimer's disease is a progressive degenerative
disease, which destroys brain cells. Currently there is no effective treatment to stop
this process and ultimately the disease is fatal. However, there are some drugs
available that appear to alleviate some of the symptoms of Alzheimer's disease in
some people.
Source: The Alzheimer Society of Ireland
Parkinson's disease 
Parkinson's disease is a slowly progressive condition, which occurs when the brain
produces insufficient quantities of the chemical dopamine. This results in many
changes relating to movement, balance and co-ordination.
Parkinson’s disease affects about one person in every 1,000. It is more common in
later years. The cause of Parkinson’s disease is not yet known, but significant
progress in understanding Parkinson's has been made in recent years.
There is no known cure at present, but medication can usually control symptoms to a
marked degree. 
Source: Parkinson’s Association of Ireland
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Microbes, parasites and your immune system
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FIGHTING DRUG-RESISTANT
YEAST INFECTIONS 
Prof David Coleman, Dr Derek
Sullivan, Dr Gary Moran, and
students Sarah Gee and
Emmanuelle Pinjon (School of
Dental Science, TCD) are hunting
for new drugs to treat Candida
dubliniensis
It’s not every day you discover a new organism
but, in 1995, our group discovered a new
species of yeast, now called Candida
dubliniensis. It causes distressing mouth
infections in elderly people, for instance, or
people with cystic fibrosis or AIDS, and in the
rare cases when it gets into the bloodstream, it
can be fatal. Yeast infections are treated with
the antifungal azole drugs, but C. dubliniensis
quickly becomes resistant. So we are studying
drug resistance in C. dubliniensis, as a prelude
to developing new antifungal drugs.
C. dubliniensis was discovered in Dublin,
but is found worldwide and has probably been
around for centuries. We believe it came to
prominence in the 1990s when AIDS patients
were given azole drugs as a precaution against
fungal infections. Ironically, this practice
probably encouraged the emergence of drug-
resistant C. dubliniensis.
We have now found that, if you give azole
drugs to C. dubliniensis in the laboratory, it
quickly becomes resistant, switching on a
‘drug pump’ protein that moves the drug
molecule out of the yeast cells. The behaviour
of this particular drug pump differs to those
found in other yeasts. Our next task is to have
the C. dubliniensis genome sequenced
(hopefully during 2004). This information will
allow us to identify the yeast’s weak points,
and hopefully lead to the development of a
new generation of antifungal drugs.
HOW VIRUSES ESCAPE THE
IMMUNE SYSTEM
Better vaccines and a better
understanding of our immune
system could come from research
being done by Prof Luke O’Neill
and PhD student Elisabeth Brint
(Biochemistry TCD) 
It is a humbling thought, but a tiny virus knows
more about our immune system than we do.
The virus in question is Vaccinia, a pox virus
widely used to vaccinate against smallpox,
and which is particularly good at evading the
immune system. We hope that, if we can
discover how Vaccinia operates, it will shed
light on our immune system, and lead to 
better vaccines.
We focused on the immune cells’ early warning
alarm system. These are the toll-like receptors,
a group of 10 recently discovered molecules
which alert your body to the presence of an
invading microbe. Normally, these trigger the
immune system to wage war on any invader,
but Vaccinia can disable the alarm, and so
survive to cause an infection. This also
explains why, very occasionally, a Vaccinia
vaccine can make some people sick.
Initially, scientists thought the toll-like
receptors recognised only bacteria, but we
showed that they also have a role in
eliminating viruses. And we have now found a
Vaccinia protein, A52R, that can disable toll-
like receptors, effectively switching off the
body’s alarm.  When we modified some
Vaccinia so that it lacked this protein, and then
infected mice with it, we found that the
disabled virus was eliminated by the mice’s
immune system much faster than the normal
virus. We believe this modified virus might
make a more effective smallpox vaccine, and
that our work has improved our understanding
of how the immune system deals with viruses.
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NEW DRUGS TO FIGHT TB
How do TB bacteria survive inside
your body? Dr Wim Meijer
(Industrial Microbiology, UCD) and
PhD student Donal Wall are
investigating
TB infection is notoriously difficult to cure. This
is partly because most TB strains are now
resistant to all the available antibiotics, and
partly because the TB bacterium,
Mycobacterium tuberculosis, can actually hide
out within the very cells of your immune
system that are supposed to detect and kill the
infection. If we could understand how the
bacteria survive inside these macrophage
immune cells, it might help scientists to design
more effective TB drugs. Unfortunately, 
M. tuberculosis is difficult to work with in the
laboratory. So instead, we are studying a close
cousin, Rhodococcus equi. This bacterium,
which also hides out in our macrophage cells,
causes a potentially fatal pneumonia in foals,
and a TB-like disease in some people. 
To date, we have discovered that, to survive
inside the cells, the invading R. equi rely on
two enzymes which allow them to feed on the
cells’ lactate and lipids. When we disable
these two bacterial enzymes, the bacteria
become weaker and are much less virulent.
Our next step is to see what else is crucial for
the bacteria’s survival in the cells, and we are
already looking at iron.  
Of course, what is true for R. equi is not
necessarily true for M. tuberculosis. But if we
can identify enzymes that are crucial for the
bacteria’s survival, and if chemists can design
drugs that block these enzymes, then we
might just have an effective new drug for TB.  
HOW FOOD POISONING CAN
AFFECT YOUR NERVES
Dr Martina Prendergast and Dr
Anthony Moran (Microbiology, NUI
Galway) are studying how a food
pathogen causes Guillain-Barré
syndrome
The symptoms start with a tingling in the
fingers and toes that can rapidly progress to
full-blown paralysis.  Fortunately, most people
who develop Guillain-Barré syndrome (GBS),
make a full recovery. But the intriguing thing is
that three-quarters of GBS cases are triggered
by an infection.  And 66% of those are caused
by Campylobacter jejuni. Found in
undercooked food and contaminated milk, 
C. jejuni is the leading bacterial cause of food
poisoning. But how does food poisoning 
trigger GBS? 
The problem arises because C. jejuni cunningly
disguises itself as a human nerve cell,
camouflaging itself in the same sugars found
on nerve cells, and fooling the immune system
into treating it as a friend, not a foe. Eventually,
however, the system notices and attacks the
invading bacteria, but unfortunately often
attacks the nerve cells too.
We have now proven that GBS is indeed an
autoimmune disease: taking the surface sugars
from the bacteria, we produced antibodies
which acted against both the bacterial sugars
and those found on nerve cells. Significantly,
our new understanding of the mechanism
involved, has enabled us to perform safety
tests on a new vaccine against C. jejuni which
the US Navy is testing, and to ensure that the
vaccine would not cause GBS.  As well as
protecting military personnel from ‘travellers
diarrhoea’, such a vaccine could benefit other
high-risk groups who are frequently exposed
to infection.
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NEW DRUGS TO TREAT
MALARIA?
Why are some immune
suppressant drugs also effective
against malaria? Dr Angus Bell and
PhD student Paul Monaghan
(Microbiology, TCD) are
investigating
Strange, but true: some immune suppressor
drugs, such as those given to people receiving
organ transplants, are also effective against
malaria. The world badly needs new malaria
drugs, but clearly immune suppressors won’t do,
because they depress people’s immune system. 
In the early 1990s, researchers in Switzerland,
among them one of us (Angus Bell), found
derivatives of these drugs which were anti-
malarial, and which did not suppress the
immune system. The company holding the
patents on these drugs did not want to
develop them as anti-malarials at that time,
however. Our idea now is to find out how these
compounds work, by identifying what they
target in the malaria parasite, then design
different drugs aimed at the same target. 
We are interested in one immune suppressant
drug, called FK506. This, we discovered,
interacts with a protein found only in the malaria
parasite, and which we call the FK binding
protein (FKBP). We have now characterised the
protein, and its functions in the parasite.
Hopefully, we can use this information to design
a drug to target the FKBP and kill the malaria
parasite, but not suppress people’s immune
systems.  Already, we are working with several
new compounds derived from FK506 and given
to us by a US biotech company. So the next
generation of anti-malaria drugs may yet come
from Irish medical research.
REDUCING THE RISK OF
ABDOMINAL ADHESIONS
Ronan Cahill, Prof HP Redmond
and Dr J Wang (Surgery, Cork
University Hospital) are looking at
ways to minimise the
complications of abdominal
surgery
Abdominal surgery always produces some
internal scarring. This is a natural reaction and
it can be a good thing, helping to limit any
infection and to support the tissue as it heals.
Frequently, however, the scars become
‘sticky’, forming adhesions that glue bits of
abdominal tissue together. And when that
happens, problems can rise: acute problems,
such as bowel obstruction; and long-term
problems, such as infertility in women, if the
fallopian tubes are affected.  Clearly, we need
to minimise the risk of these peritoneal 
adhesions occurring, but without eliminating
scarring altogether.
From previous studies elsewhere, we know
that adhesions are more likely if there is some
infection (as might happen with a burst bowel).
We also know they are due in part to
inflammation at the site; the mechanism was
not clear, but it was thought the immune
system’s mast cells were involved. Working on
special laboratory mice which have almost no
mast cells, we have now shown that they
seldom develop adhesions. This confirms the
role of inflammation and mast cells, and
suggests that we might be able to minimise
adhesions if we could find a way of damping
the action of the mast cells. In a separate
study, again on laboratory mice, we found that
applying special anti-bacterial solutions during
an operation will significantly reduce the risk of
adhesions. These solutions are occasionally
used in transplant operations, but following
this study, a US company is now looking at
their wider use in abdominal surgery. 
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Life and death of cells
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WHAT CONTROLS WHEN 
CELLS DIE? 
Prof Seamus Martin and PhD
student Helen Conroy (Genetics,
TCD) are studying the chain of
events involved in apoptosis
You have spaces between your fingers
because, when you were developing in the
womb, the cells that filled those spaces
selectively died off, leaving the individual
digits. The missing cells did not die
haphazardly, but through a process of
programmed cell death called apoptosis. This
process, involving the controlled demolition of
cells with minimal disturbance to neighbouring
cells, is used to eliminate cells that are no
longer required or that are a potential threat.
We see it not just in development, but also
where cells are undergoing constant renewal
(all dividing tissues), and where cells are
damaged, infected or simply aged.  
Apoptosis is controlled by a family of proteins
called caspases, that are present in all cells
and activated at the onset of apoptosis. Once
the caspases are activated, the cell is
committed to dying and there is no going
back. In this research, we identified two new
proteins (called NAC and ASC) that activate
caspases and hence trigger cell death. Our
next step is to identify the conditions in the cell
that activate these proteins, and so initiate the
chain of events that ends with the cell’s death. 
TOO MUCH OF A GOOD THING
CAN BE BAD FOR YOU
Dr William Watson and PhD
student Belinda Doyle (Mater
Hospital, Dublin and the Conway
Institute of Biomolecular and
Biomedical Research, UCD) are
studying why some blood cells
don’t die when they should
Wounds normally come with infections, so our
body’s ‘wound response’ includes a massive
attack on any invading bacteria. This attack is
mounted by neutrophils, a type of white blood
cell that produces toxins to kill the pathogens.
Unfortunately, some people undergoing major
surgery find that their body perceives the
operation as a wound and, though there is no
infection, responds with a flood of neutrophils.
This can lead to potentially fatal disorders,
such as systemic inflammatory response
syndrome, triggered partly by the toxins the
neutrophils produce. 
To understand why this can arise, we need to
understand a neutrophil’s life cycle. This short-
lived cell normally survives in the blood for
about six hours, then dies by a process of
controlled suicide, called apoptosis. We
believe that inappropriate inflammatory
responses happen if apoptosis is delayed, and
the cells are prevented from dying. The
proteins that control apoptosis include
inhibitors, which prevent it happening too
early, and caspases, which actually trigger
apoptosis. The balance between these
determines whether a neutrophil lives or dies,
and for apoptosis to happen, production of the
inhibitors must be switched off, and the
caspases switched on.
Working with neutrophils taken from patients
who have suffered an acute inflammatory
response, we discovered a particular protein
that is important in inhibiting apoptosis in
these cases. It seems these neutrophils don’t
die because they have not matured properly,
information which may be useful in helping us
to treat these inflammatory diseases.
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THE FREIGHT CONTROLLERS 
OF THE CELL
Dr Mary McCaffrey, Dr Deborah
Wallace and Andrew Lindsay
(Biochemistry, UCC) study how
nutrients are transported in and out
of cells
Haemochromatosis is a disease that develops
when too much iron is absorbed through the
gut. Our bodies can’t cope with the excess, so
unless blood is removed or lost, the iron will
accumulate leading to complications.  It’s just
one example of what can happen when the
machinery that controls the transport of
nutrients in and out of cells becomes faulty.  
To discover what is going on, we study the
proteins involved in controlling these 
transport processes.
The main controllers are the Rab proteins, 60
or so enzymes that regulate the transport of
‘cellular freight’. Rab4, for instance, helps sort
through the molecular freight that has arrived
in the cell; and Rab11 controls the transport of
appropriate freight back to the cell surface
(recycling). By studying these enzymes, we
have identified six other proteins involved in
this process, called the ‘Rab11-family
interacting proteins’ (FIPs). Sophisticated
biotechnology techniques allow us to pinpoint
where in a cell the proteins are active, and we
are now characterising the FIPs, most of which
interact with Rab11 at the recycling depots. It
has also become clear that Rab11 and FIP4
are also involved in the upheaval that happens
when a cell divides to form two daughter cells.
New cell membrane must be put in place then,
and we believe the Rab and FIP proteins play
a role in controlling this movement. Our next
step is to understand what is happening at the
molecular level, work which may ultimately
help us to understand diseases such as
haemochromatosis.
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Genes, cells and disease
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HOW DO ANAESTHETICS WORK?
Why do some anaesthetics
occasionally cause a potentially
fatal side effect? Work by Prof Kay
Ohlendieck (Biology, NUI
Maynooth), Prof James Heffron
(Biochemistry, UCC), and PhD
student Louise Glover, could lead
to safer anaesthetics with fewer
side-effects
Anaesthetic gases are wonderful drugs that
make modern surgery possible. Unfortunately,
some of these narcotics occasionally cause
severe, even life-threatening side effects. And
because scientists still don’t know how they
work, we also don’t know what causes these
dangerous side effects.
Our research team is interested in halothane,
an anaesthetic which can trigger a rare, but
potentially fatal problem called malignant
hyperthermia; about one person in a
thousand is at risk. In malignant hyperthermia,
the patient’s temperature rises quickly, and
their muscles become very rigid; hopefully,
they will survive, but their heart, lungs and
kidneys will probably be damaged.
To understand how malignant hyperthermia
happens, we looked at halothane’s effect on
muscle cells, comparing muscle samples taken
from normal people and from people who are
sensitive to halothane (and at risk of
developing malignant hyperthermia). We
discovered that the drug activates a muscle
protein which is involved in converting nerve
signals into muscular contractions: when the
drug activates the protein, it releases a flood of
calcium ions, triggering severe contractions
and the malignant hyperthermia. The difference
between ‘sensitive’ and ‘normal’ muscle is
clear-cut: sensitive muscle reacts at very low
doses of the drug whereas normal muscles
react only to very high doses. 
Our discovery is an important step in
understanding how anaesthetics work, and
explaining malignant hyperthermia. The result,
which has just been published internationally,
will hopefully lead to the design of safer drugs
with fewer side-effects.
A 10,000 YEAR OLD DISEASE
When Prof David Croke and his
PhD student Jonathon Flanagan
(Biochemistry, Royal College of
Surgeons in Ireland) studied the
genetics of galactosaemia, they
discovered it arrived here with the
first settlers
Every child born in Ireland is tested at birth for
a number of genetic diseases, including
galactosaemia. About 1% of Irish people carry
a galactosaemia mutation, and people who
inherit a mutation from both of their parents
cannot convert galactose (one of the milk
sugars) into glucose. This serious and
potentially fatal disorder must be detected
early, hence the infant screening programme.  
There are, however, several forms of
galactosaemia, each caused by a different
mutation. The most common one in Ireland,
Q188R, is due to a mutation in the GALT
(galactose-1-phosphate uridyltransferase) gene
on chromosome 9. We know from other
European studies that the various mutations
arose at different times in history. By studying
the DNA sequences that surround the Q188R
mutation, we sought to learn more about its
history, and hence also the genetic history of
the Irish people.
Comparing DNA samples donated by 350
galactosaemia patients from all over Europe,
we discovered that the Q188R mutation is
about 10,000 years old, so it probably arrived
here with the first settlers from Europe about
9,000 years ago. This kind of genetic
information is increasingly useful, first, in
designing screening programmes, and second,
because scientists now know that some drugs
for certain diseases work best in people with a
particular genetic make-up. Our work here
continues, and we are now studying why some
forms of Q188R are more severe than others. 
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NEW WAYS TO TREAT A BRITTLE
BONE DISEASE?
Dr Jane Farrar, Prof Pete
Humphries, Dr Paul Kenna, 
Dr Sophia Millington-Ward and 
PhD student Danny Allen
(Genetics, TCD) are hoping to
develop a treatment for an
inherited form of brittle bone
disease
Osteogenesis imperfecta (OI) is a genetic
disease that results in brittle bones. The root
cause is a fault in a gene that codes for
collagen, which is essential for the body’s
skeleton. The severity of OI varies widely,
however: some people are so badly affected
that they die young, while others develop only
a mild form of the disease. As yet, there is no
effective treatment. 
The reason OI is so variable, and so difficult to
treat, is because there are actually many
different forms of the disease: to date,
scientists have identified over 150 different
mutations in the collagen gene in question.
Each one is different, yet each one produces
faulty collagen and the net result is brittle
bones. Developing a separate treatment for
each mutation would be unrealistic, not to say
uneconomic, so we are experimenting with a
more generic technique that would hopefully
treat a large number of the OI variations.
The approach uses something called a
‘hammerhead ribozyme’, essentially a special
type of RNA molecule designed to detect and
destroy the transcripts produced by most
forms of the collagen gene. When we added
our ribozyme to cells growing in culture in the
laboratory, we found that it successfully
suppressed 50% of the abnormal collagen
genes. This is a very promising result, and our
next step will be to test our compound in mice
that have osteogenesis imperfecta.
WHEN DENTAL PULP IS
INFLAMED
A better understanding of how
teeth function may come from
research by Dr Michael O'Sullivan,
Prof Keith Tipton and PhD student
Jeff O'Sullivan (Dental School, and
Biochemistry TCD)
The dental pulp inside your teeth contains
nerves, blood vessels, and specialised pulp cells
that carry out the normal metabolic processes
and also synthesise dentine, the hard coating on
teeth. Being surrounded by hard tissue, the pulp
cells have problems if they ever become
inflamed (‘pulpitis’), because they have little
room to expand. We might find ways to prevent
the problem if we could understand what
happens when dental pulp is inflamed.
One potentially toxic compound involved in
inflammation is an amine called serotonin. In
dental pulp, serotonin is removed (oxidised) by
a specialised amine oxidase enzyme (SSAO).
This SSAO is doubly interesting because, in
many tissues it also promotes inflammation to
fight infection, by directing white blood cells to
the infected site. We have shown that these
two activities are connected: to redirect white
blood cells SSOA must oxidise amines, such
as serotonin. SSOA activity may also be
necessary for normal dental pulp development.
Intriguingly, SSOA is also of interest in
diabetes, because its amine oxidation function
seems to be important in stimulating cells to
utilise glucose, at least in some tissues. Like
the white blood cell trafficking, this glucose
stimulation happens only when the enzyme
oxidises amines, and the activity of SSAO is
increased in diabetes. Thus, SSAO is
multifunctional, playing various important roles.
Developing ways to alter its activity could help
in dealing with inflammatory conditions such
as pulpitis, and in reducing the consequences
of diabetes.
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WHEN LESS IS MORE
Dr John Laffey and Prof Paul
McLoughlin (Physiology, UCD) are
studying how best to treat lung
failure
It’s counterintuitive, but sometimes a ventilator
can harm a patient’s lung. Ventilators help
patients with lung failure to breathe; otherwise,
their blood oxygen level would fall, carbon
dioxide (the waste product of breathing) would
accumulate, and their blood would become
more acidic. This hypercapnic acidosis (HA),
was generally considered ‘a bad thing’. 
Recently, however, studies showed that a
ventilator forcing a ‘full breath’ into a damaged
lung can injure what is left of the lung. In 2000,
researchers proved that lowering the intensity
of ventilation actually saves patients’ lives.
Intensive care doctors now reduce the volume,
and ‘tolerate’ the resulting HA. But some
scientists, among them Prof Brian Kavanagh in
Toronto, and one of us (John Laffey), wondered
what the HA was doing, and if it was part of the
body’s attempts to alleviate the lung damage?
We set out to explore this in a system
resembling the acute lung failure that results
from serious infections, which is the
commonest and most severe form of acute
lung failure. When we induced lung failure in
rats in the laboratory, put them on a ventilator
and gave them carbon dioxide, we found that
the acidosis reduced the inflammation in their
lungs, improved blood oxygen levels and
decreased lung damage. We now think the HA
reduces the production of the toxic chemicals
that occur during lung injury. These
encouraging results have major implications for
how patients with acute lung failure are
treated, and we plan to extend our studies to
other types of lung injury.
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FAECAL INCONTINENCE
FOLLOWING DELIVERY
Rhona Mahony and Prof Colm 
O’ Herlihy (Obstetrics and
Gynaecology, UCD, and the
National Maternity Hospital) are
studying the causes of and
treatment of faecal incontinence
after women give birth
Injury to the ‘back passage’ or anal sphincter
is a recognised complication of vaginal
delivery, and it can lead to faecal incontinence.
In about 3% of vaginal deliveries, the anal
sphincter can tear, for instance, or the nerve
supplying the muscle can be damaged. This
probably accounts for the fact that, while 4%
of people develop some faecal incontinence
during their life, the problem is eight times
more common in women than men. 
To identify women who might be at particular
risk, we studied a group of women expecting
their second baby and who had evidence of
anal sphincter injury following their first vaginal
delivery. We found that women with an
identifiable defect in the sphincter were indeed
at risk of developing symptoms of faecal
incontinence following further vaginal delivery.
Diabetic women, however, who because of
their diabetes have subtle nerve abnormalities
which might affect muscle function, did not
appear to be at any additional risk. We also
studied 400 women whose anal sphincter had
torn during delivery and found that, while 56%
of patients had some symptoms, only 7% had
severe problems with faecal incontinence. 
Finally, we compared different ways of
managing anal sphincter injuries, and found it
was better to use a laxative than a
constipating agent in the days immediately
following the delivery. Biofeedback
physiotherapy, a form of ‘pelvic floor’ exercise,
was also effective and helped 80% of the
women in our study to reduce their symptoms.
TESTING FOR PRE-ECLAMPSIA
IN PREGNANCY
Dr Bridgette Byrne and MSc
student Aoife Crowley (Coombe
Women's Hospital, and Royal
College of Surgeons Ireland) are
trying to identify women at risk of
developing pre-eclampsia
Pre-eclampsia is relatively common in
pregnancy, with symptoms that include high
blood pressure and oedema (swelling) in the
mother. Fortunately, most cases are mild, but in
severe cases, the baby might be born small, or
must be delivered prematurely. On occasion,
the disease may be severe enough to threaten
the mother’s life. No one yet knows what
causes the condition, and this makes it all the
more difficult to identify women at risk. But
there is one clue: women with pre-eclampsia
have more of their baby’s cells circulating in
their bloodstream than other women.
All pregnant woman have some foetal cells
crossing into their bloodstream, a phenomenon
called ‘foetal trafficking’. We think the foetal
cells are important in teaching the mother’s
immune system to recognise the foetus as
‘friend’ and not ‘foe’, and so ensure a healthy
pregnancy. Some studies found that this foetal
trafficking increases before pre-eclampsia
develops, which suggests we could use it to
predict women at risk. However, when we
measured foetal trafficking in pregnant women
during the first three months of pregnancy, we
found no significant difference between those
who later developed pre-eclampsia and those
who did not. This suggests that the increased
foetal trafficking seen during pre-eclampsia
might be a consequence of, and not a cause of
the condition.
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THE GENETICS OF
SCHIZOPHRENIA
Dr Aiden Corvin, Prof Michael Gill
and colleagues (Psychiatry/
Genetics, St James's Hospital,
Dublin and TCD) have identified a
gene that is associated with
schizophrenia
Schizophrenia and bipolar affective disorder
(sometimes called manic depression) are
important psychotic disorders that together
affect about 2% of people. We know that genes
can play an important role in illness and that
there is often a strong family susceptibility to
becoming ill. However, little is known about
which genes are important or whether the same
genes might be involved in these two diseases.
Research from Iceland suggested a gene,
Neuregulin-1, might be implicated in
schizophrenia, so we decided to look for this
gene in the Irish population. Over 300 people
who have schizophrenia and/or bipolar
affective disorder (and 250 healthy blood
donors) helped us by donating blood, which
we analysed for neuregulin-1. 
Our results confirm that neuregulin-1 is
indeed associated with schizophrenia
(though not with bipolar affective disorder):
about 21% of people with schizophrenia have
the gene, compared with 15% in the general
population. Interestingly, we found the same
form of the gene contributes to susceptibility in
Ireland and in Scotland, but that this is subtly
different to that seen in Iceland.
There has been considerable international
interest in our findings, and we are now
investigating other genes involved in
schizophrenia and bipolar affective disorder, as
well as studying what neuregulin-1 does.
Current schizophrenia drugs target the body’s
dopamine pathways, but neuregulin-1 is
involved in a different pathway, the glutamate
system. So, if we can learn more about
neuregulin-1 and glutamate, it might lead to a
new generation of schizophrenia treatments.
THE BENEFITS OF LEADERSHIP
TRAINING
Michael Watts and Trudy Meehan
(GROW Mental Health
Organisation, Kilkenny) found that
training group leaders benefits all
group members
Mutual-help groups are a cost effective
element in the health service. But to be
successful, it is essential that every group
member feels psychologically safe within their
group. This means that those who lead the
group meetings must be skilled in noticing and
responding appropriately to participants
needs. To help ensure this, GROW has
developed a training programme for group
leaders. The programme was monitored and
evaluated by the Department of Applied
Psychology at UCC, who helped us to refine
the final version of the course manual. 
We found that people who took the course
developed a greater awareness of the
psychological vulnerability of group members,
and learned ways to deal with difficulties that
can arise, either directly themselves or by
referring the person to mainstream services.
An unexpected but very positive outcome was
that those who took the course gained the
confidence to go back to further education in
work-related areas.
This project was co-funded by the Calouste
Gulbenkian Foundation.
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A CHANGE OF HEART
Changing your lifestyle after a
heart attack is not easy. Carol
Condon and Prof Geraldine
McCarthy (School of Nursing and
Midwifery, UCC) investigate the
challenges
Over-protective family members, and difficulty
managing stress . . . just some of the problems
facing people who are trying to change their
lifestyle after a heart attack. It is essential that
people succeed in making these changes, to
minimise their chances of another attack. So
we thought it was important to hear from the
patients themselves about the problems 
they faced.
We interviewed ten people six weeks after they
were discharged from hospital. Although in the
early days after their heart attack all had been
enthusiastic about making changes, they were
finding it harder than they had expected.
Quitting smoking and managing stress were
particularly difficult. There was the added
problem of trying to change too many things at
once. Overprotective family members were a
major source of frustration. Significantly, those
interviewed had little knowledge about
community support services, and even where
they were aware of such services, did not feel
these would be of benefit, believing they had to
cope with making lifestyle changes on their own.
On the plus side, all ten were looking forward to
the future and trying to resume normal life.
Based on this survey, we recommend: more
primary care services providing professional
support in the community; a nurse-led
telephone support service (which does not wait
for the patients to call); stress management
programmes; improved cardiac rehabilitation
services; an individualised approach to care
based on assessing each patient’s needs; and
long-term follow-up of patients.
NEW NEEDS MEAN NEW
SERVICES
Mary McCarron, Dr Cecily Begley
and Prof Michael Gill (School of
Nursing & Midwifery Studies, TCD)
looked at the special needs of
people who have Down’s
syndrome and dementia
Thanks to improved healthcare, people with
Down’s syndrome are living longer. But there is
a problem: as people with Down’s syndrome
age, they are more likely to develop dementia –
indeed, as many as 40% of those aged over 35
show some signs of dementia. Existing
healthcare services are not yet aware of or able
to meet the particular needs of these people.
To assess this growing problem, we monitored
the daily assistance needed by people who
have both Down’s syndrome and dementia. We
found that those with even moderate dementia
need on average eight hours assistance each
day (those with no dementia need less than
three hours). As the dementia progresses, their
needs also change: at mid-stage, they need
someone to monitor their wandering, for
instance; later they will need considerable
nursing care. Existing resources for people with
Down’s syndrome (e.g. community group
homes) are not equipped or designed for
people with dementia.  Equally, conventional
dementia support services lack the expertise to
treat people with Down’s syndrome (e.g.
communication difficulties, and assessing
someone with underlying intellectual disability).
We therefore urgently recommend: early
screening and dementia assessment for
people with Down’s syndrome;  education and
training for staff, families and other health care
professionals; and the immediate provision of
additional resources to reorient and redesign
care facilities and services, both day and
residential, to ensure humane and appropriate
care for this increasingly at risk population.  
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NURSES, MOTHERS AND THE
PUBLIC HEALTH SERVICE –1
Sinead Hanafin looked at some of
the factors that can influence the
quality of the public health nursing
service
Good relationships are essential in life, and the
dealings public health nurses have with
families are no exception. To look at the
factors that can influence relations between
public health nurses and mothers, I surveyed
nurses and managers working across the Irish
public health services, and I also interviewed a
number of mothers with babies.
Most new mothers have their first contact with
a public health nurse in the days after they
return home following the birth of their child.
However, if the nurse does not hear about the
birth in time, or does not contact the family
until later, it can influence all future
interactions.  Significantly, I found that if the
first contact comes early, the family usually
views the service as helpful.  But if the first
contact is late, families frequently conclude
that the service is interested only in ensuring
that children are not neglected or ill treated.
I also identified other issues that can affect the
quality of the service provided.  These
included, for example, home visiting; having a
suitably equipped, warm, clean, safe, child-
friendly, local health centre; having up-to-date,
relevant and specific advice and information;
and, finally, following up problems that arose.
Significantly, I found that although some
families had many needs, almost all families
had some needs, and that these can change
as the infant develops.  Perhaps most
important of all, is that these needs can be
met through the public health nursing service.
NURSES, MOTHERS AND THE
PUBLIC HEALTH SERVICE – 2
Helen Mulcahy and Prof Geraldine
McCarthy (Nursing Studies, UCC)
looked at some of the issues that
can arise for nurses and mothers
of vulnerable families
Some mothers, especially first-time mothers,
may need extra support after their baby is
born.  The local public health nurse might
class such a family as "vulnerable", a term that
is used in legislation and public health reports.
But could such a label compromise relations
between the nurse and the client?  And could
that affect the quality of service delivered?
We studied the relationships between ‘mothers
of vulnerable families’ and public health
nurses, to see if there were differences in
attitudes, perceptions, needs and
expectations, interviewing 44 mothers of
infants who had been identified as ‘vulnerable’,
and their nurse. The overall response from
nurses and mothers was positive, and most
valued the relationship and found it "highly
participatory".  Most mothers said they felt
comfortable with the nurse and were glad of
the support. Some suggested they would have
appreciated additional visits, however, and for
the nurse to be more available in the weeks
immediately following the child’s birth.  Nurses,
though they might see a need for, and want to
give additional help, reported being
constrained by a lack of resources. Our
recommendations include, for instance, that
nurses should consult families about their
needs; and they should not assume mothers
will make contact in the event of a problem,
especially by telephone.  Given the importance
of first impressions, we recommend special
training for those in community work.  We
suggest further studies to follow nurse-mother
relationships over time, and to investigate why
so many of those classed as ‘vulnerable’ are
first-time mothers.
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TO FLUORIDATE OR NOT TO
FLUORIDATE
Dr Paul Beirne (University Dental
School, Cork) considers the public
health and policy implications of
opposing viewpoints
The debate over public water fluoridation has
run for over 50 years, with strong ‘pro’ and
‘anti’ fluoridation camps holding entrenched
views. Supporters describe fluoridation as ‘one
of the ten great public health achievements of
the twentieth century’. Opponents, on the
other hand, label it as ‘the greatest scientific
fraud, possibly of all time'.  To understand
these opposing viewpoints I analysed the
scientific, popular and alternative media
reporting on the issues. I sought to understand
how opponents and proponents perceive the
risks of fluoridation and interpret the scientific
evidence. I also considered approaches to
making public policy decisions under
conditions of uncertainty advocated by
opposing sides of the conflict. 
My analysis of the media reporting reveals that
the interpretation of scientific evidence is
subjective and heavily influenced by the
interpreter’s preconceived beliefs. People for
and against fluoridation have, it seems, very
different ‘world views’: it is not just fluoridation
they disagree on; they also have very different
attitudes to hierarchies and social structures,
and towards the merit of ‘expert’ opinions. The
implications of these findings are that these
opposing perspectives will never be
reconciled.  Yet, these differing viewpoints
must be understood and taken into account if
we are to have real dialogue and public
involvement in decision-making. This would be
an important first step in developing public
health policies that are widely supported.  The
findings of this analysis also apply to other
areas of public policy which are hotly debated,
from vaccination to incineration. 
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COMPARING CANCER SERVICES
ACROSS IRELAND 
Dr Harry Comber, Dr Marie Reilly
and researcher Salah Mahmud
(National Cancer Registry, Cork)
have studied cancer statistics for
the various health board areas
The National Cancer Registry has been
collecting data on the incidence and treatment
of all cancers in Ireland since 1994 and on
cancer deaths up to the end of 2000, which
has resulted in a valuable database. We
decided to analyse this information to
investigate whether the survival rates for
cancer patients were significantly different in
different parts of the country, and if so,
whether this was related to the type of cancer,
perhaps, or the type of patient (perhaps rural
patients are more likely to be older, for
instance), or different forms of cancer
treatment that regional health boards provided.
For this study, we looked at the four most
common cancers in Ireland (breast, colorectal,
lung and prostate), and analysed all cases
newly diagnosed by the National Cancer
Registry in the five years 1994-98. Almost half
of all the cancer patients were treated in the
Eastern Region Health Authority (ERHA), so we
took this as our baseline for the comparisons.
We found significant differences in the survival
rates of patients with breast or colorectal
cancer between the ERHA and the rest of the
country, even after taking account of other risk
factors such as patient age and stage of
cancer. The differences in survival for prostate
and lung cancer patients were slight, however.
This is as expected because these two
cancers are not as sensitive to treatment
differences as breast and colorectal 
cancers are.
IMPROVING HOSPITAL
OUTPATIENT SERVICES
Orla Keegan and Prof Hannah
McGee (Psychology, Royal College
of Surgeons Ireland), are helping
hospitals to assess the service
they provide
Anyone who has waited for an outpatient
appointment, knows that the system can usually
be improved. The problem is that, though
outpatient appointments are a scarce resource,
they are difficult to manage efficiently because
they are influenced by so many factors, such as
patients who don’t show, and consultants’
timetables. To help hospitals examine the
system they operate, we have developed
outpatient questionnaires (one for those who
attend, one for those who fail to show).
Testing these at several outpatient clinics in
the eastern region, we found general
satisfaction with the level of medical care, but
considerable dissatisfaction with the outpatient
‘system’. For instance, over half waited an
hour longer than they deemed acceptable.
Significantly, we found that most people are
prepared to wait within reason, but want to
know in advance how long they might be
waiting and, having waited, expect a
reasonable consultation time. One-quarter said
the physical conditions were poor (e.g. quality
of waiting area), and people also resented
being told to return a second time for other
tests. Up to one-third of patients don’t attend
for their appointment, whether because they
have recovered, are too ill or simply forget.
Knowing their views, and encouraging them to
cancel their appointment in advance, can help
a hospital improve its service and release
appointments for others in the waiting list. Our
questionnaires can therefore yield valuable
information for hospitals, and we have now
produced a training manual so that managers
can conduct their own surveys.
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PROVIDING NEUROPHYSIOLOGY
SERVICES IN REMOTE AREAS
Mary Fitzsimons and PhD student
Lisa Ronan (Neuroscience Division,
Beaumont Hospital, Dublin) believe
that telemedicine could provide a
valuable service
The northwest of Ireland has no clinical
neurophysiological service. So patients who
need electroencephalography, for instance,
must travel to Dublin or Galway.
Understandably, people sometimes decide that
the long round trip is just too much. While the
equipment needed is minimal (just a computer,
amplifier and electrodes), you do also need a
technician and, to provide a full service, a
consultant neurophysiologist. There are only a
handful of these in Ireland, however, mostly in
the main cities.  With ‘telemedicine’, local
doctors could gain access to these experts,
but are there enough patients in the northwest
to warrant a telemedicine service?
To estimate the likely demand, we conducted a
thorough audit of patients who use the eastern
region’s neurophysiological services (including
patients travelling from the northwest), and we
compared the numbers with those seen in
Britain.  We discovered that there is
considerably less use of neurophysiological
services here, even in the eastern region, and
even more so in the northwest. The
Association of British Clinical
Neurophysiologists recommends services for
640 patients per 100,000 population per year.
Our audit revealed that current clinical
neurophysiology activity in the Eastern
Regional Health Authority reaches only about
half that level, and for the Northwest Health
Board it is half that again (23% of the British
recommended level). This suggests that, if a
telemedicine service was available in the
northwest, many more people would avail of it
than currently make the journey to Dublin.
Clearly, such a service would greatly improve
patient care in remote areas. 
This project was co-funded by the North
Western Health Board.
THE BELIEFS AND BEHAVIOUR
OF CARDIAC PATIENTS
Dr Molly Byrne, Prof Andrew
Murphy and Dr Jane Walsh
(Department of General Practice,
NUI Galway) have studied how
people’s perceptions can affect
how they manage their disease
Primary preventive care targets people who
have not yet become ill, while secondary
preventive care is aimed at preventing ill
people from getting worse. So, for heart
disease patients, secondary prevention might
be aimed at preventing another heart attack,
and could include measures such as
medication, and lifestyle changes. Secondary
prevention could make a tremendous
difference to someone with coronary heart
disease, but do all patients comply with the
recommended measures? And do a person’s
beliefs and perceptions play any part in this?
To assess secondary prevention measures
among cardiac patients, we gathered data on
1,611 patients in the Western and
Northwestern Health Board Regions, including
information on medication, diet and exercise.
As an example of our findings, 53% were
following the recommended low-fat diet, but
22% were still on a high-fat diet. We also
interviewed the patients to determine their
perceptions about their illness and treatment,
to see if we could relate their behaviour to their
perceptions.
We found that people who believed their
medication was necessary and had few
concerns about side-effects, were more likely to
take the drugs. But we found little association
between people’s perception of their disease,
and their willingness to make lifestyle changes:
many of those who realised their disease was
serious, had not yet changed their behaviour.
This could be because heart disease is a
chronic condition that for many people does not
result in many symptoms. Clearly, secondary
prevention programmes will need to take
account of this if they are to be effective.
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KEEP TAKING THE TABLETS
Dr Martin Henman, Lisa Vivero
(Pharmacology, TCD) and Kate
Mulvenna (NEHB primary care
pharmacist) looked at how
community pharmacists can help
patients to take their medicine
Imagine for a moment that you have a chronic
coronary condition. Your GP has prescribed
drugs that will minimise your chances of a heart
attack in years to come but, right now, you have
no symptoms. Question: would you take the full
prescribed dose every day? Or would you
sometimes decide you didn’t need to? 
Increasingly, it’s recognised that people with
chronic conditions, such as high blood
pressure, do not always take their medication
as prescribed. To investigate whether
community pharmacists can help improve
people’s knowledge of their medicine, we ran a
pilot scheme with several pharmacists. They
contacted a sample of their regular customers
who were taking at least two cardiac
medications, and offered advice about the
medication. They also gave the customers a
short questionnaire to ascertain their
understanding of the medicine and their
general compliance with the prescription.  This
revealed that while some patients were well-
informed, others had limited information.  In
these latter cases, the pharmacist was then
able to provide information and advice.
Crucially, our questionnaire also revealed that
many people take less of their medication than
is recommended. In these cases, the
pharmacist was able to ascertain why (the
person might have been concerned about
side-effects, for instance), and if need be refer
them to their GP for further help. To this end,
the pilot project worked well, and we now have
plans to expand it.
This project was co-funded by the North
Eastern Health Board.
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APPENDIX – IMAGES
The following images were supplied by the Wellcome Trust
photographic library:
Scanning electron micrograph (SEM) of normal red blood cells 6
Sphygmomanometer showing a high blood pressure reading 7
Molecular model of the insulin molecule 10
Insulin phial and syringe 11
Human breast cancer cells dividing 14
Breast cancer cells in culture 17
Transmission electron micrograph (TEM) of a lymphoblast, 
an abnormal cell occuring in lymphoblastic leukaemia 19
Confocal image of human T cells in culture 20
Section through the small intestine showing villi 22
SEM of colony of Helicobacter bacteria 23
SEM of Campylobacter bacteria 24
Confocal image of an Alzheimer's brain showing a an amyloid plaque 26
Confocal image of the brain showing nerve cells in yellow (image 1) 27
Confocal image showing the nerve cell bodies in the brain (image 2) 27
Serpentine cord mycobacteria Mycobacterium tuberculosis 32
Malaria carrying mosquito on human skin 35
Confocal image of human cells showing two cells undergoing apoptosis 38
TEM image of a polymorphonuclear leucocyte or neutrophil (image 2) 39
Human chromosomes in the anaphase stage of cell division (mitosis) 40
Human cells in culture, stained to show the DNA within the nuclei (blue),
the mitochondia (red) and the endoplasmic reticulum (green). 42
Separation of DNA fragments by electrophoresis 43
Region of growth in an immature thigh bone 44
Computed tomography (CT) scan of lungs 45
A polarized light micrograph of dopamine crystals 53
Magnetic resonance imaging equipment (MRI), operator’s view 63
Assortment of pills and vitamin tablets 65
The following images were supplied by HRB funded
researchers:
Immunohistochemical staining for p16 in cervical lesions. 
Image supplied by Prof John O’Leary and Niamh Murphy. 16
Staining for cytosolic calcium in colon cancer cells. Image provided by 
Dr David Croke, Dr Aideen Long, Eilis Foran and Dr Yuri Volkov. 18
Photomicrograph of neurones in culture. Image provided by Dr Kieran 
McDermott, Dr Aideen Sullivan and Terri Wood. 28
Cervical cancer cells undergoing apoptosis. Image provided by Prof
Seamus Martin and Helen Conroy (image 1). 39
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